Janssen outlines pipeline ambitions
pharmafile | May 24, 2013 | News story | Research and Development, Sales and Marketing | Janssen, Johnson and Johnson, pipeline
Janssen has outlined plans to submit ‘more than ten’ new product filings worldwide in the next four years, along with more than double that number of what it calls ‘significant brand line extensions’.
Speaking to analysts this week, the Johnson & Johnson subsidiary mapped out its pipeline, which includes hepatitis C drug simeprevir, already filed in Japan, Europe and the US, where the FDA has granted it Priority Review status.
The company wants new products to account for nearly half of all pharma sales by 2017, and points out 11 new product launches since 2009 which have driven 12 consecutive quarters of operational sales growth.
Other big hopes for Janssen are cancer drugs ibrutinib and daratumumab, to which the FDA has given Breakthrough Therapy Designations, and sirukumab and guselkumab for immune mediated diseases.
The company also has plans for a three-month formulation of schizophrenia drug Invega plus novel vaccines for influenza, rabies and polio.
Last year Janssen’s pipeline suffered a setback when the Alzheimer’s drug bapineuzumab it was developing with Pfizer proved to be no better than placebo.
The company is keen to stress its ambitions in the Asia-Pacific region, with three new molecular entities (NMEs) and three brand line extensions currently registered in Japan, with two more NMEs and six brand extensions planned by 2017.
Janssen already has four NMEs and four extensions registered in China, with plans for nine and six more, respectively, over the next four years.
“Our investment in transformational innovation has enabled strong growth that has allowed us to continue investing in our future portfolio,” said Paul Stoffels, J&J’s chief scientific officer.
The company has seen more NME approvals per year at a lower development cost than the industry average, he went on.
“With a steadfast focus on the most serious unmet medical needs, our approach is to identify the best science – internal and external – to deliver new options and solutions to patients,” Stoffels added.
IMS Health reports that J&J’s pharma business was the fastest growing in the US, Europe and Japan in 2012, with sales of $25.4 billion.
“We’ve spent the past five years transforming our business, and the growth we’re seeing today is the direct impact of that effort,” said Joaquin Duato, pharma group worldwide chairman.
“With strong momentum across our global Pharmaceuticals segment, we are executing well against our commercial strategy to gain market share and ensure greater access to our medicines,” he concluded. “We’re also strengthening our presence in critical geographies and have nearly doubled our footprint in emerging markets during the last five years.”
Adam Hill
Related Content
GSK enters agreement for license for JNJ-3089 for development of bepirovirsen
GSK and Arrowhead Pharmaceuticals have announced that they have come to an agreement with Janssen …
Janssen and Sanofi enter agreement for potential vaccine programme
Janssen Pharmaceuticals, a Johnson & Johnson company, has announced a development and commercialisation agreement with …
Janssen submits sNDA to FDA for full approval of Balversa
The Janssen Pharmaceutical Companies of Johnson & Johnson has announced the submission of a supplemental …
